Drug may curb female infertility from cancer treatments

September 1, 2017 by Krishna Ramanujan
A mouse ovary with proteins specific to oocytes labelled in red and yellow. The study reports that culturing such ovaries in the presence of a drug that inhibits DNA damage checkpoint enzymes protects the oocytes from lethal levels of radiation that would normally kill the entire oocyte reserve (small oocytes in picture). Credit: Schimenti Lab, Cornell University

An existing drug may one day protect premenopausal women from life-altering infertility that commonly follows cancer treatments, according to a new study.

Women who are treated for with radiation or certain chemotherapy drugs are commonly rendered sterile. According to a 2006 study from Weill Cornell Medicine, nearly 40 percent of all female breast cancer survivors experience premature ovarian failure, in which they lose normal function of their ovaries and often become infertile.

Women are born with a lifetime reserve of oocytes, or immature eggs, but those oocytes are among the most sensitive cells in the body and may be wiped out by such cancer treatments.

The current study, published in the journal Genetics, was led by John Schimenti, Cornell University professor in the Departments of Biomedical Sciences and Molecular Biology and Genetics. The study builds on his 2014 research that identified a so-called checkpoint protein (CHK2) that becomes activated when oocytes are damaged by radiation.

CHK2 functions in a pathway that eliminates oocytes with DNA damage, a natural function to protect against giving birth to offspring bearing new mutations. When the researchers irradiated mice lacking the CHK2 gene, the oocytes survived, eventually repaired the DNA damage, and the mice gave birth to healthy pups.

The new study explored whether the checkpoint 2 pathway could be chemically inhibited.

"It turns out there were pre-existing CHK2 inhibitor drugs that were developed, ironically enough, for , but they turned out not to be very useful for treating cancer," said Schimenti, the paper's senior author. Vera Rinaldi, a graduate student in Schimenti's lab, is the paper's first author. "By giving mice the inhibitor drug, a small molecule, it essentially mimicked the knockout of the checkpoint gene," Rinaldi said.

By inhibiting the checkpoint pathway, the oocytes were not killed by radiation and remained fertile, enabling birth of normal pups.

"The one major concern," Schimenti said, "is that even though these irradiated oocytes led to the birth of healthy mouse pups, it's conceivable that they harbor mutations that will become manifested in a generation or two, because we are circumventing an evolutionarily important mechanism of genetic quality control. This needs to be investigated by genome sequencing."

When doctors recognize the need for -damaging cancer treatments, women may have their oocytes or even ovarian tissue removed and frozen, but this practice delays treatment. Also, when women run out of oocytes, women's bodies naturally undergo menopause, as their hormonal systems shift.

"That is a serious dilemma and emotional issue," Schimenti said, "when you layer a cancer diagnosis on top of the prospect of having permanent life-altering effects as a result of chemotherapy, and must face the urgent decision of delaying to freeze oocytes at the risk of one's own life."

The study sets a precedent for co-administering this or related drugs and starting cancer therapy simultaneously, though such interventions would first require lengthy human trials.

"While humans and mice have different physiologies, and there is much work to be done to determine safe and effective dosages for people, it is clear that we have the proof of principle for this approach," Schimenti said.

Explore further: Protein that culls damaged eggs identified, infertility reversed

Related Stories

Protein that culls damaged eggs identified, infertility reversed

January 30, 2014
(Medical Xpress)—A new discovery by Cornell researchers may lead to therapies that allow women who are made infertile by radiation or chemotherapy treatments to have children.

Blocking apoptotic response could preserve fertility in women receiving cancer treatments

May 17, 2016
Female cancer patients of reproductive age could preserve their fertility during radiation and chemotherapy through treatments that target the DNA damage response in oocytes (the cells that develop into eggs), an approach ...

Mouse study looks at safety of stem cell therapy for early menopause

May 18, 2017
Now that we know that egg-making stem cells exist in adult rodents and humans and that these cells can be transplanted into mice with premature ovarian failure to produce offspring, the next question is to assess whether ...

Preventing eggs' death from chemotherapy

June 17, 2013
Young women who have cancer treatment often lose their fertility because chemotherapy and radiation can damage or kill their immature ovarian eggs, called oocytes. Now, Northwestern Medicine scientists have found the molecular ...

The more eggs the better in IVF?

July 3, 2017
A higher number of eggs retrieved in an IVF treatment cycle is independently associated with more chromosomally normal embryos available for transfer, according to a new Australian study. However, the benefit of a greater ...

Recommended for you

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

Liquid biopsy results differed substantially between two providers

December 14, 2017
Two Johns Hopkins prostate cancer researchers found significant disparities when they submitted identical patient samples to two different commercial liquid biopsy providers. Liquid biopsy is a new and noninvasive alternative ...

Testing the accuracy of FDA-approved and lab-developed cancer genetics tests

December 14, 2017
Cancer molecular testing can drive clinical decision making and help a clinician determine if a patient is a good candidate for a targeted therapeutic drug. Clinical tests for common cancer causing-mutations in the genes ...

Newest data links inflammation to chemo-brain

December 14, 2017
Inflammation in the blood plays a key role in "chemo-brain," according to a published pilot study that provides evidence for what scientists have long believed.

One in five young colon cancer patients have genetic link

December 13, 2017
As doctors grapple with increasing rates of colorectal cancers in young people, new research from the University of Michigan may offer some insight into how the disease developed and how to prevent further cancers. Researchers ...

5 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

somefingguy
1 / 5 (1) Sep 02, 2017
Is it really a smart thing to do though, let people who are predisposed to cancer breed again?
MarsBars
5 / 5 (1) Sep 04, 2017
Is it really a smart thing to do though, let people who are predisposed to cancer breed again?

I'm curious, somefingguy - does your comment apply equally to people who have prostate cancer or testicular cancer?
somefingguy
1 / 5 (1) Sep 06, 2017
Is it really a smart thing to do though, let people who are predisposed to cancer breed again?

I'm curious, somefingguy - does your comment apply equally to people who have prostate cancer or testicular cancer?


Yes, it does. Cancer usually indicates a lot of mutations which you would not want to pass on. I am not against trying to save those people, but perhaps we shouldn't let them pass on clearly mutated (not a positive mutation) DNA.
MarsBars
5 / 5 (1) Sep 07, 2017
Cancer usually indicates a lot of mutations which you would not want to pass on. I am not against trying to save those people, but perhaps we shouldn't let them pass on clearly mutated (not a positive mutation) DNA.

Given that, in most cases, breast cancer, prostate cancer and (to a somewhat lesser extent) testicular cancer arises after the person has already reproduced, how would society go about implementing and policing a policy such as you are proposing? How successful do you think efforts would be in convincing the existing offspring of post-reproductive cancer sufferers from reproducing? How do you envision preventing them from doing so, particularly when there would also be religious opposition and human rights opposition in addition to opposition from the individuals themselves? How would you clearly distinguish between cancers resulting from a genetic legacy and cancers due to environmental or personal behavior causes?
Captain Stumpy
5 / 5 (1) Sep 08, 2017
perhaps we shouldn't let them pass on clearly mutated (not a positive mutation) DNA
@somefingguy
i downrated your posts because they don't take anything into consideration (google scholar is your friend - use it)

this attitude is especially heinous given that we have successfully modified DNA - https://www.ncbi.nlm.nih.gov

the problem with it is: the morality of requested or forced alterations to DNA in utero (IOW- sans choice)

in point of fact: the biological imperative to reproduce is one of the most driving instincts of any living creature on earth (only the need to survive outweighs this one)

moreover, mixing DNA is how we evolved - mutation is a chance that we take every time we reproduce

.

so what about mitigating factors like exposure?

do ya suggest offing all those folk too because they don't have the requisite DNA to fight said exposure like other animals or insects?

where is the line drawn?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.